
    
      This is a prospective, open, non-randomized, study involving two (2) centers in the United
      States. A minimum of twelve (12) and a maximum of fifteen (15) subjects will be consented,
      treated and have blood samples drawn to evaluate the pharmacokinetic parameters of sirolimus
      release from the Svelte DES.
    
  